Next Article in Journal
Spatial Trade-Offs and Temporal Evolution of Multiple Ecosystem Services in a Marine-Terrestrial Urban-Agglomeration Zone
Previous Article in Journal
Tissue Distribution and Immunomodulation in Channel Catfish (Ictalurus punctatus) Following Dietary Exposure to Polychlorinated Biphenyl Aroclors and Food Deprivation
Open AccessArticle

Serum Sclerostin But Not DKK-1 Correlated with Central Arterial Stiffness in End Stage Renal Disease Patients

1
Division of Metabolism and Endocrinology, Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi 62247, Taiwan
2
Division of Nephrology, Buddhist Tzu-Chi General Hospital, Hualien 97004, Taiwan
3
School of Medicine, Tzu-Chi University, Hualien 97004, Taiwan
4
Division of Nephrology, Department of Medicine, Hsin-Jen Hospital, New Taipei City 24243, Taiwan
5
Division of Nephrology, Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi 62247, Taiwan
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Int. J. Environ. Res. Public Health 2020, 17(4), 1230; https://doi.org/10.3390/ijerph17041230
Received: 12 January 2020 / Revised: 11 February 2020 / Accepted: 11 February 2020 / Published: 14 February 2020
Sclerostin and dickkopf-1 (DKK1) played a role in the development of cardiovascular diseases and arterial stiffness in chronic kidney disease (CKD) patients but with controversial results of patients in end-stage renal disease (ESRD) including hemodialysis (HD) and peritoneal dialysis (PD). This study aimed to examine the association between the mode of dialysis or the values of sclerostin or DKK1 and carotid-femoral pulse wave velocity (cfPWV) in ESRD patients. There were 122 HD and 72 PD patients enrolled in this study. By a validated tonometry system, cfPWV was measured and then segregated patients into values of >10 m/s as the high central arterial stiffness (AS) group and values ≤ 10 m/s as the control group. Serum levels of sclerostin and DKK1 were measured using a commercial enzyme-linked immunosorbent assay kit. Possible risk factors for the development of AS were analyzed by logistic regression analysis. There were 21 (29.2%) of PD and 53 (43.4%) of HD in the high AS group. Compared to patients in the control group, those in the high AS group were older, had more comorbidities, had higher systolic blood pressure, and had higher serum levels of fasting glucose, C-reactive protein, and sclerostin. Levels of sclerostin (adjusted OR 1.012, 95% CI. 1.006–1.017, p = 0.0001) was found to be an independent predictor of high AS in ESRD patients by multivariate logistic regression analysis. Furthermore, receiver operating characteristic curve analysis showed the optimal cut-off values of sclerostin for predicting AS was 208.64 pmol/L (Area under the curve 0.673, 95% CI: 0.603–0.739, p < 0.001). This study showed that serum levels of sclerostin, but not DKK1 or mode of dialysis, to be a predictor for high central AS in ESRD patients. View Full-Text
Keywords: arterial stiffness; carotid–femoral pulse wave velocity; end-stage renal disease; Dickkopf-1; hemodialysis; peritoneal dialysis; aclerostin arterial stiffness; carotid–femoral pulse wave velocity; end-stage renal disease; Dickkopf-1; hemodialysis; peritoneal dialysis; aclerostin
Show Figures

Figure 1

MDPI and ACS Style

Wu, C.-F.; Hou, J.-S.; Wang, C.-H.; Lin, Y.-L.; Lai, Y.-H.; Kuo, C.-H.; Liou, H.-H.; Tsai, J.-P.; Hsu, B.-G. Serum Sclerostin But Not DKK-1 Correlated with Central Arterial Stiffness in End Stage Renal Disease Patients. Int. J. Environ. Res. Public Health 2020, 17, 1230.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop